Molecular biology and clinical implication of hepatitis C virus

Abstract

Hepatitis C virus (HCV) was first described in 1989 as the putative viral agent of non-A non-B hepatitis. It is a member of the Flaviviridae family and has been recognized as the major causative agent of chronic liver disease, including chronic active hepatitis, cirrhosis and hepatocellular carcinoma. HCV is a positive RNA virus with a genome containing approximately 9500 nucleotides. It has an open reading frame that encodes a large polyprotein of about 3000 amino acids and is characterized by extensive genetic diversity. HCV has been classified into at least 6 major genotypes with many subtypes and circulates within an infected individual as a number of closely related but distinct variants known as quasispecies. This article reviews aspects of the molecular biology of HCV and their clinical implication.

Introduction

Hepatitis C virus (HCV) was first described in 1989 as the putative viral agent of non-A non-B hepatitis (1). It is a member of the Flaviviridae family and has been recognized as the major causative agent of chronic liver disease, including chronic active hepatitis, cirrhosis and hepatocellular carcinoma (2). The overall prevalence of anti-HCV antibodies in the United States is 1.4% (3.9 million people). The estimated number of actively infected individuals is 2.7 million. In Brazil, the overall prevalence of anti-HCV antibodies ranges from 1.5 to 1.7% among the general population and blood donors.

Genomic organization of hepatitis C virus

HCV is a positive RNA virus with a genome containing approximately 9500 nucleotides. It has an open reading frame that encodes a large polyprotein of about 3000 amino acids. When cleaved by viral and host enzymes this polyprotein produces 10 polypeptides. The genomic organization of HCV consists of a 5' untranslated region (5' UTR) of about 340 base pairs and downstream to the 5' UTR there are regions that encode the following proteins: “core”, envelope 1, envelope 2, p7, non-structural region 2, non-structural region 3 (NS3), non-structural regions 4A and 4B, and non-structural regions 5A and 5B (NS5A and NS5B) (Figure 1). Downstream to this coding region there is another untranslated region of approximately 200 nucleotides (3' UTR).

The 5' UTR is highly conserved and therefore is the target for diagnostic assays. It has a complex secondary structure and is the putative internal ribosome entry site, with an
RNA sequence that directs the ribosomes to initiate translation (3).

The HCV core has RNA binding capacity and appears to be associated with the HCV genome. It has been suggested that this protein induces hepatic steatosis in transgenic mice and is an important factor in the development of hepatocellular carcinoma in patients with chronic HCV infection (4). Serum quantification of the core protein by ELISA correlates with serum levels of HCV RNA.

HCV envelope 1 and envelope 2 proteins have molecular masses of approximately 31 and 70 kDa, respectively. They interact with each other and may be a heterodimer. The envelope 1 region is used for genotyping for clinical purposes. The first 81 nucleotides of the envelope 2 region are thought to be the hypervariable region 1 (HVR1) of HCV (5). HVR1 appears to induce the production of neutralizing antibodies and could function as a decoy to help the virus escape the immune system. HCV envelope 2 is thought to have binding sites for CD81, a protein expressed in the membranes of mammalian cells that might be implicated in the entry of HCV into the hepatocyte (6-8). NS3 protein has protease and helicase activities (9). Its helicase activity participates in the process of RNA unwinding during replication. The NS5A region has a particular nucleotide sequence that may determine the sensitivity of the virus to interferon therapy (interferon sensitivity determination region) (10,11). Nevertheless, other investigators have reported discordant results and this issue is controversial (12,13). An in vitro study did not find a relationship between interferon sensitivity determination region and sensitivity to interferon (14).

The NS5B region has motifs characteristic of an RNA-dependent RNA polymerase, an enzyme responsible for viral replication (15).

**Genetic heterogeneity of hepatitis C virus**

As is the case for other RNA viruses, HCV has a high genetic heterogeneity. The estimated mutation rate in the human organism is $1.92 \times 10^{-3}$ nucleotide site$^{-1}$ year$^{-1}$ (16). This genetic diversity is not evenly distributed in the viral genome. The non-coding regions are relatively conserved, while the envelope regions, especially HVR1, have the highest mutation rate. This genetic diversity resulted in the classification of HCV into at least 6 major genotypes (1 to 6) and many subtypes, based on the analysis of the NS5 region (17-23). Different genotypes may differ by 30 to 35% of their viral genomes, while subtypes may differ by 15-20% of their nucleotide sequences.

Several studies have suggested that HCV genotype 1b might be associated with greater severity of liver disease than other HCV genotypes, including the development of hepatocellular carcinoma (24,25). However, other investigators have not confirmed these data, and this issue remains unresolved (26,27). On the other hand, it has been well established that patients chronically infected with HCV genotype 1 isolates respond less favorably to therapy with interferon or pegylated interferon alone or in combination with ribavirin compared to patients infected with HCV genotype 2 or 3 (28,29).

It is interesting to note that HCV circulates...
as a population of different but closely related genomes, known as quasispecies, whose sequences differ only by a few nucleotides (30). These variants may be generated by nucleotide substitutions occurring due to lack of fidelity of the HCV RNA-dependent RNA polymerase, as observed with other RNA viruses. The variants present at any time may be determined by a combination of viral fitness and response to immune pressure.

The existence of a quasispecies population appears to hamper the development of vaccines for HCV and to favor the perpetuation of the virus in the human organism. In a study of 12 patients with acute hepatitis C, Farci et al. (31) observed that individuals who developed chronic infection had a significantly greater HVR1 genetic diversity after 8 to 11 weeks compared to patients who eliminated the virus during the acute phase.

The influence of HCV quasispecies on the response to therapy with alpha interferon has been analyzed by many investigators (32-36). Although the results were not uniform, a higher HVR1 complexity and diversity before treatment appeared to be more frequently observed among non-responders.

The role of HCV quasispecies in the severity of recurrent hepatitis C after liver transplantation has been evaluated in several studies. Gretch et al. (37) studied 3 patients with severe recurrent hepatitis C and 2 with mild recurrence of the disease. HVR1 genetic diversity was higher in the mild group compared to the severe group. In another study with a larger number of patients, the same group of investigators obtained similar results (38). On the other hand, Pessoa et al. (39) obtained contradictory findings. In a study of 6 patients with fibrosing cholestatic HCV after transplant and 6 patients with mild recurrence of the disease, these investigators found a greater HVR1 diversity among patients with severe recurrent hepatitis C. We studied 11 patients who underwent transplantation for HCV-related cirrhosis and developed recurrent hepatitis C (40). Patients were divided into two groups according to the stage of hepatic fibrosis detected in follow-up biopsies after transplantation. The mild group had stage 1 or 2 fibrosis while the severe group had stage 3 or 4. After liver transplantation, a more complex HCV HVR1 quasispecies population was associated with mild recurrence of the disease. Among those patients in whom recurrent hepatitis C led to severe disease, the number of HVR1 non-synonymous substitutions was greater than the number of synonymous substitutions. Interestingly, the regions flanking HVR1 had a similar pattern of genetic evolution in patients from the mild and severe groups. This suggests that the difference in the alterations observed in HVR1 did not occur sporadically. The highest degree of change in viral amino acid sequences occurred within the first 36 months after transplantation.

It has been suggested that partially mismatched primers may preferentially amplify different HVR1 sequences in a heterogeneous virus population. This suggests a possible mechanism of bias during the amplification of HVR1 sequences and may be responsible for some conflicting data regarding the evolutionary or clinical implications of HCV quasispecies (41).

After liver transplantation, we have demonstrated that the quasispecies nature of two putative regions of CD81-binding sites located in the E2 region appears to remain conserved (Lyra AC, Fan X and Di Bisceglie AM, unpublished data).

When liver transplantation is carried out in a situation in which both donor and recipient are infected with hepatitis C, only one viral strain, either the strain from the donor or the strain from the recipient, predominates and persists up to 4 years after surgery. The two strains are not detected at the same time. This suggests that hepatitis C co-infection after liver transplantation is not a frequent finding (42).
Conclusions

The application of sophisticated techniques of molecular biology over the last 10 years has led to remarkable advances in the knowledge of the molecular structure of HCV. Studies on HCV replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems. Recently, efficient initiation of HCV RNA replication in cell-based systems was reported for full-length RNAs derived from genotype 1b isolates, and later for full-length RNAs derived from genotype 1a strain H77 (14,43,44). These cell-based systems should be useful for basic replication studies and for the development of antiviral agents. New therapies for treating hepatitis C are in various stages of preclinical and clinical development. These include nucleic acid-based approaches (antisense and ribozymes), small molecule inhibitors of essential HCV-encoded enzymes (protease, helicase, and polymerase), immune modulation, and immunotherapy.

References


